Treatments in Respiratory Medicine

, Volume 4, Issue 2, pp 107–116

Management of Influenza Virus Infections with Neuraminidase Inhibitors

Detection, Incidence, and Implications of Drug Resistance
Therapy In Practice

Abstract

Although influenza vaccination remains the primary method for the prevention of influenza, efficacy may be limited by a poor match between the vaccine and circulating strains and the poor response of elderly patients. Hence, there is an important role for antiviral therapy in the management of influenza. While amantadine and rimantadine have been available for the treatment of influenza in some countries for several years, they are only effective against influenza A viruses, they can have neurological and gastrointestinal adverse effects, and resistant virus is rapidly generated. Neuraminidase inhibitors, a new class of drug, are potent and specific inhibitors of all strains of influenza virus, and they have minimal adverse effects. The greatest benefit is seen in those patients presenting <30 hours after development of influenza symptoms, those with severe symptoms or those in high-risk groups. In addition to treatment of the infection, both drugs are effective prophylactically and have been shown to limit spread of infection in close communities, such as families and in nursing homes. No resistant virus strains have been isolated from normal individuals treated with zanamivir. Resistant virus can be isolated from approximately 1% of adults and 5% of paediatric patients with influenza treated with oseltamivir. However, infectivity of mutant viruses is generally compromised. Governments spend millions of dollars on influenza vaccination campaigns; however, once influenza virus is circulating in the community, vaccination cannot limit the spread of disease. A greater promotion of the use of neuraminidase inhibitors for the treatment and prevention of influenza could have a significant impact on limiting its spread. This could result in saving millions of dollars, not only in direct costs associated with medical and hospital care, but also significant savings in indirect costs associated with the loss of productivity at work, school and home environments. For the benefit of all communities, there needs to be a greater awareness of the symptoms of influenza and the efficacy of neuraminidase inhibitors in disease treatment.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179–86PubMedCrossRefGoogle Scholar
  2. 2.
    Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362: 1733–45PubMedCrossRefGoogle Scholar
  3. 3.
    Ruest A, Michaud S, Deslandes S, et al. Comparison of the Directigen flu A+B test, the Quick Vue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol 2003; 41: 3487–93PubMedCrossRefGoogle Scholar
  4. 4.
    Nicholson KG. Managing influenza in primary care. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1999Google Scholar
  5. 5.
    Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun Dis Public Health 2000; 3: 32–8PubMedGoogle Scholar
  6. 6.
    Brocklebank JT, Court SD, McQuillin J, et al. Influenza-A infection in children. Lancet 1972; II: 497–500CrossRefGoogle Scholar
  7. 7.
    Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. London: Blackwell Science Ltd, 1998: 358–72Google Scholar
  8. 8.
    Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661–5PubMedCrossRefGoogle Scholar
  9. 9.
    von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418–23CrossRefGoogle Scholar
  10. 10.
    Palese P, Tobita K, Ueda M, et al. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974; 61: 397–410PubMedCrossRefGoogle Scholar
  11. 11.
    Colman PM, Ward CW. Structure and diversity of influenza virus neuraminidase. Curr Top Microbiol Immunol 1985; 114: 177–255PubMedCrossRefGoogle Scholar
  12. 12.
    Aoki F. Amantadine and rimantadine. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1995: 457–76Google Scholar
  13. 13.
    Keyser LA, Karl M, Nafziger AN, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000; 160: 1485–8PubMedCrossRefGoogle Scholar
  14. 14.
    Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176: 119–30PubMedCrossRefGoogle Scholar
  15. 15.
    Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocom- promised adults. Clin Infect Dis 1998; 26: 1418–24PubMedCrossRefGoogle Scholar
  16. 16.
    Grambas S, Bennett MS, Hay AJ. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology 1992; 191: 541–9PubMedCrossRefGoogle Scholar
  17. 17.
    Houck P, Hemphill M, LaCroix S, et al. Amantadine-resistant influenza A in nursing homes: identification of a resistant virus prior to drug use. Arch Intern Med 1995; 155: 533–7PubMedCrossRefGoogle Scholar
  18. 18.
    Ziegler T, Hemphill ML, Ziegler ML, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999; 180: 935–9PubMedCrossRefGoogle Scholar
  19. 19.
    Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119: 681–90PubMedCrossRefGoogle Scholar
  20. 20.
    Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000; 43: 3482–6PubMedCrossRefGoogle Scholar
  21. 21.
    Stoll V, Stewart KD, Maring CJ, et al. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Biochemistry (Mosc) 2003; 42: 718–27CrossRefGoogle Scholar
  22. 22.
    Kati WM, Montgomery D, Carrick R, et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother 2002; 46: 1014–21PubMedCrossRefGoogle Scholar
  23. 23.
    Masuda T, Shibuya S, Arai M, et al. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorg Med Chem Lett 2003; 13: 669–73PubMedCrossRefGoogle Scholar
  24. 24.
    Honda T, Yoshida S, Arai M, et al. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Bioorg Med Chem Lett 2002; 12: 1929–32PubMedCrossRefGoogle Scholar
  25. 25.
    Macdonald SJ, Watson KG, Cameron R, et al. Potent and long-acting dimeric inhibitors of influenza virus meuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother 2004; 48: 4542–9PubMedCrossRefGoogle Scholar
  26. 26.
    Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother 2001; 2: 1671–83PubMedCrossRefGoogle Scholar
  27. 27.
    McKimm-Breschkin JL. Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin Pharmacother 2002; 3: 103–12PubMedCrossRefGoogle Scholar
  28. 28.
    McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs 2001; 61: 263–83PubMedCrossRefGoogle Scholar
  29. 29.
    Cheer SM, Wagstaff AJ. Zanamivir: an update of its use in influenza. Drugs 2002; 62: 71–106PubMedCrossRefGoogle Scholar
  30. 30.
    McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother 2001; 35: 57–70PubMedCrossRefGoogle Scholar
  31. 31.
    Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir. Lancet 2004; 364(9436): 759–65PubMedCrossRefGoogle Scholar
  32. 32.
    Hoffken G, Gillissen A. Efficacy and safety of zanamivir in patients with influenza: impact of age, severity of infections and specific risk factors. Med Microbiol Immunol (Berl) 2002; 191: 169–73CrossRefGoogle Scholar
  33. 33.
    Murphy KR, Eivindson APK, Stein WJ, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest 2000; 20(5): 337–45CrossRefGoogle Scholar
  34. 34.
    US Food and Drug Administration, Center for Drug Evaluation and Research. NDA21-087 Tamiflu (Oseltamivir Phosphate) capsule [online]. Available from URL: http://www.fda.gov/cder/foi/nda/99/21087_Tamiflu.htm [Accessed 2003 Aug 6]
  35. 35.
    Johnson RJ, Schweinle JE, Burroughs S. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice. Clin Drug Invest 2000; 20(5): 327–36CrossRefGoogle Scholar
  36. 36.
    Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people’s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001; 322: 577–9PubMedCrossRefGoogle Scholar
  37. 37.
    Johnson RJ, Schweinle JE, Burroughs S. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice. Clin Drug Invest 2000; 20(5): 327–36CrossRefGoogle Scholar
  38. 38.
    Silagy C, Watts R. Zanamivir, a new targeted therapy in the treatment of influenza: a patient perspective assessed by questionnaire. Clin Drug Invest 2000; 19: 111–21CrossRefGoogle Scholar
  39. 39.
    Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127–33PubMedCrossRefGoogle Scholar
  40. 40.
    Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240–6PubMedCrossRefGoogle Scholar
  41. 41.
    Wooltorton E. Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ 2004; 170: 336PubMedGoogle Scholar
  42. 42.
    McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and streptococcus pneumoniae. J Infect Dis 2003; 187: 1000–9PubMedCrossRefGoogle Scholar
  43. 43.
    McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47: 2264–72PubMedCrossRefGoogle Scholar
  44. 44.
    Tumpey TM, Garcia-Sastre A, Mikulasova A, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 2002; 99: 13849–54PubMedCrossRefGoogle Scholar
  45. 45.
    Leneva IA, Goloubeva O, Fenton RJ, et al. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001; 45: 1216–24PubMedCrossRefGoogle Scholar
  46. 46.
    Leneva IA, Roberts N, Govorkova EA, et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48: 101–15PubMedCrossRefGoogle Scholar
  47. 47.
    CSIRO. CSIRO based drug effective against bird flu [online]. Available from URL: http://www.csiro.au/index.asp7.type=mediaRelease&docid=PrBird-Flu5&style=mediaRelease [Accessed 2004 Feb 20]
  48. 48.
    CDC. Update on Influenza A(H5N1) and SARS: interim recommendations for enhanced US surveillance, testing, and infection control [online]. Available from URL: http://www.cdc.gov/flu/han020302.htm [Accessed 2004 Feb 12]
  49. 49.
    Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363: 617–9PubMedCrossRefGoogle Scholar
  50. 50.
    Kuiken T, Rimmelzwaan GF, Van Amerongen G, et al. Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol 2003; 40: 304–10PubMedCrossRefGoogle Scholar
  51. 51.
    Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282: 31–5PubMedCrossRefGoogle Scholar
  52. 52.
    Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families: Zanamivir Family Study Group. N Engl J Med 2000; 343: 1282–9PubMedCrossRefGoogle Scholar
  53. 53.
    Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186: 1582–8PubMedCrossRefGoogle Scholar
  54. 54.
    Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine- resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000; 21: 700–4PubMedCrossRefGoogle Scholar
  55. 55.
    Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000; 5: 205–13PubMedGoogle Scholar
  56. 56.
    Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43PubMedCrossRefGoogle Scholar
  57. 57.
    Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54PubMedCrossRefGoogle Scholar
  58. 58.
    Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep 2001; 27: 37–40PubMedGoogle Scholar
  59. 59.
    Peters PHJ, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025–31PubMedCrossRefGoogle Scholar
  60. 60.
    McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors: a review. Antiviral Res 2000; 47: 1–17PubMedCrossRefGoogle Scholar
  61. 61.
    Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001; 49: 147–56PubMedCrossRefGoogle Scholar
  62. 62.
    Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257–62PubMedCrossRefGoogle Scholar
  63. 63.
    Abed Y, Bourgault AM, Fenton RJ, et al. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 2002; 186: 1074–80PubMedCrossRefGoogle Scholar
  64. 64.
    McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996; 40: 40–6PubMedGoogle Scholar
  65. 65.
    Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the alpha-2,6-si-alyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77: 8418–25PubMedCrossRefGoogle Scholar
  66. 66.
    Varghese JN, Smith PW, Sollis SL, et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998; 6: 735–46PubMedCrossRefGoogle Scholar
  67. 67.
    Jackson HC, Roberts N, Wange ZM, et al. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Invest 2000; 20: 447–54CrossRefGoogle Scholar
  68. 68.
    Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41: 742–50PubMedCrossRefGoogle Scholar
  69. 69.
    Molla A, Kati W, Carrick R, et al. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol 2002; 76: 5380–6PubMedCrossRefGoogle Scholar
  70. 70.
    Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70: 1818–27PubMedGoogle Scholar
  71. 71.
    Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug- resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348: 867–8PubMedCrossRefGoogle Scholar
  72. 72.
    Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103: 199–203PubMedCrossRefGoogle Scholar
  73. 73.
    Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 2002; 54: 99–111PubMedCrossRefGoogle Scholar
  74. 74.
    Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55: 307–17PubMedCrossRefGoogle Scholar
  75. 75.
    Herlocher ML, Truscon R, Elias S, et al. Transmission studies in ferrets of influenza viruses resistant to the antiviral oseltamivir. J Infect Dis 2004; 190(9): 1627–30PubMedCrossRefGoogle Scholar
  76. 76.
    Vogel GE. Neuraminidase inhibitors in the management of influenza: experience of an outpatient practice. Med Microbiol Immunol (Berl) 2002; 191: 161–3CrossRefGoogle Scholar
  77. 77.
    Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis 2003; 35: 52–8PubMedCrossRefGoogle Scholar
  78. 78.
    Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 2002; 113: 300–7PubMedCrossRefGoogle Scholar
  79. 79.
    Da Silva PR, Nguyen VT, Hayward AC. Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care. J R Soc Med 2003; 96: 66–9PubMedCrossRefGoogle Scholar
  80. 80.
    Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999; 36Suppl. 1: 51–8PubMedCrossRefGoogle Scholar
  81. 81.
    Cox RJ, Mykkeltvedt E, Sjursen H, et al. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine 2001; 19: 4743–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.CSIRO Health Sciences and NutritionParkvilleAustralia

Personalised recommendations